Literature DB >> 19430753

[Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].

K C Kähler1, A Hauschild.   

Abstract

The growing number of patients treated with modern targeted therapies that cause specific cutaneous side effects is drawing attention to the optimal management of these side effects. Experience to date has shown that good management allows the majority of patients to receive the treatment as planned. As a result of the link between dermatological side effects and the success of treatment than can be assumed to exist for many substances, interdisciplinary collaboration between dermatologists and professionals from other disciplines working in the field of oncology is becoming increasingly important.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430753     DOI: 10.1007/s00105-009-1754-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  16 in total

1.  Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.

Authors:  Jörg Thomas Hartmann; Lothar Kanz
Journal:  Arch Dermatol       Date:  2008-11

2.  Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption.

Authors:  Elisabeth Eiling; Michael Brandt; Thomas Schwarz; Axel Hauschild
Journal:  Arch Dermatol       Date:  2008-09

Review 3.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

4.  Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

Authors:  D Strumberg; A Awada; H Hirte; J W Clark; S Seeber; P Piccart; E Hofstra; D Voliotis; O Christensen; A Brueckner; B Schwartz
Journal:  Eur J Cancer       Date:  2006-01-19       Impact factor: 9.162

5.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

6.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

7.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Authors:  Román Pérez-Soler; Abraham Chachoua; Lisa A Hammond; Eric K Rowinsky; Mark Huberman; Daniel Karp; James Rigas; Gary M Clark; Pedro Santabárbara; Philip Bonomi
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

8.  Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib.

Authors:  Philipp Ivanyi; Thomas Winkler; Arnold Ganser; Christoph Reuter; Viktor Grünwald
Journal:  Dtsch Arztebl Int       Date:  2008-03-28       Impact factor: 5.594

9.  Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.

Authors:  C-H Yang; W-C Lin; C-K Chuang; Y-C Chang; S-T Pang; Y-C Lin; T-T Kuo; J-J Hsieh; J W C Chang
Journal:  Br J Dermatol       Date:  2007-12-06       Impact factor: 9.302

10.  Dose-dependent severe cutaneous reactions to imatinib.

Authors:  S Ugurel; R Hildenbrand; E Dippel; A Hochhaus; D Schadendorf
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more
  2 in total

Review 1.  Cutaneous side effects of new antitumor drugs: clinical features and management.

Authors:  Ralf Gutzmer; Andreas Wollenberg; Selma Ugurel; Bernhard Homey; Arnold Ganser; Alexander Kapp
Journal:  Dtsch Arztebl Int       Date:  2012-02-24       Impact factor: 5.594

Review 2.  [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].

Authors:  A Wollenberg; M Staehler; T Eames
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.